PMID- 20832191
OWN - NLM
STAT- MEDLINE
DCOM- 20110809
LR  - 20110404
IS  - 1768-3114 (Electronic)
IS  - 0369-8114 (Linking)
VI  - 59
IP  - 2
DP  - 2011 Apr
TI  - [Acute human herpesvirus 6 (HHV-6) infections: when and how to treat?].
PG  - 108-12
LID - 10.1016/j.patbio.2010.07.015 [doi]
AB  - The pathogenicity of human herpesvirus 6 (HHV-6) still raises numerous questions. 
      Acute HHV-6 infections correspond to primary infections, reactivations or 
      exogenous reinfections. The expression of related clinical symptoms is highly 
      variable but may be extremely severe, particularly among immunocompromised 
      patients. The prototypic severe disease associated with these infections is 
      limbic encephalitis occurring in stem cell transplant recipients. The diagnosis 
      of acute HHV-6 infections relies on the quantitation of viral load in whole blood 
      by means of quantitative PCR. The demonstration of HHV-6 causative role in the 
      genesis of clinical symptoms requires additional investigations such as the 
      search for HHV-6 DNA in cerebrospinal fluid in case of encephalitis. The 
      chromosomal integration of HHV-6 DNA is a rare event among HHV-6-infected 
      subjects but may alter the interpretation of virological results. Therapy with 
      ganciclovir, foscarnet or cidofovir has not yet clear indications but, at the 
      current stage of knowledge, only concerns the treatment of highly symptomatic 
      infections. The usefulness of prophylactic or pre-emptive antiviral chemotherapy 
      has not yet been convincingly demonstrated. Treatment efficacy must be checked 
      through a clinical and virological follow up, based in part on quantitative PCR 
      approaches. Controlled studies are urgently needed with the goal of evaluating 
      the cost-effectiveness of HHV-6 follow up and therapy in different clinical 
      situations.
CI  - Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.
FAU - Agut, H
AU  - Agut H
AD  - Service de virologie, ER1 DETIV UPMC, CERVI, groupe hospitalier 
      Pitie-Salpetriere, 83, boulevard de l'Hopital, 75651 Paris, France. 
      henri.agut@psl.aphp.fr
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Infections aigues a herpesvirus humain 6 (HHV-6) : quand et comment traiter ?
DEP - 20100915
PL  - France
TA  - Pathol Biol (Paris)
JT  - Pathologie-biologie
JID - 0265365
RN  - 0 (Antiviral Agents)
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Acute Disease
MH  - Antiviral Agents/therapeutic use
MH  - DNA, Viral/cerebrospinal fluid/genetics
MH  - Hematopoietic Stem Cell Transplantation/adverse effects
MH  - *Herpesvirus 6, Human/pathogenicity
MH  - Humans
MH  - Immunocompromised Host
MH  - Limbic Encephalitis/cerebrospinal fluid/drug therapy/etiology/virology
MH  - Opportunistic Infections/drug therapy/virology
MH  - Polymerase Chain Reaction
MH  - Roseolovirus Infections/diagnosis/drug therapy/prevention & 
      control/transmission/*virology
MH  - Viral Load
MH  - Viremia/virology
MH  - Virus Integration
EDAT- 2010/09/14 06:00
MHDA- 2011/08/10 06:00
CRDT- 2010/09/14 06:00
PHST- 2010/07/01 00:00 [received]
PHST- 2010/07/30 00:00 [accepted]
PHST- 2010/09/14 06:00 [entrez]
PHST- 2010/09/14 06:00 [pubmed]
PHST- 2011/08/10 06:00 [medline]
AID - S0369-8114(10)00102-1 [pii]
AID - 10.1016/j.patbio.2010.07.015 [doi]
PST - ppublish
SO  - Pathol Biol (Paris). 2011 Apr;59(2):108-12. doi: 10.1016/j.patbio.2010.07.015. 
      Epub 2010 Sep 15.